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ABSTRACT
NF-xB was first identified as a postive regulator which
bound to a 10 bp sequence in the first intron of the Igx
light chain gene. Further characterization of this
transcription factor has revealed that NF-xB is kept
from binding to its consensus sequence by its inhibitor,
IkB-a, which retains NF-xB in the cytoplasm. Upon
receiving various extra- and intracellular signals, IxB-
ca is rapidly degraded and NF-xB is induced to
translocate into the nucleus. This process precedes the
rapid induction of IxB-a mRNA and protein. To
understand how IxB-ci is replenished, we have cloned
and sequenced the 5' flanking region of the IxB-a gene
and have identified the transcription start site and three
NF-xB sites in this region. Further characterization of
these NF-xB sites show that they have different
affinities for three specific protein complexes which we
identify here to consist of various members of the Rel
family. In transient assays, cotransfection with a p65
expression vector is able to activate an IxB-a promoter-
CAT reporter construct and all three NF-xB sites are
required for full activation of the IxB-ci gene following
stimulation with TNF-ca. Our data confirm a
transcriptional autoregulatory loop involved in
maintaining appropriate NF-xB and IxB-a levels in the
cell.
INTRODUCTION
NF-xB and its cytoplasmic inhibitor, IxB-a, belong to the
Rel/ankyrin family of transcription factors. The p65 (Rel A) and
p50 (NF-xBl) subunits of NF-xkB and other members of this
family including p52 (yt-10, NF-xB2) and the drosophila
maternal morphogen, dorsal, share homology with the DNA
binding and dimerization domains of the product of the proto-
oncogene, c-rel (for review, see references 1, 2, and references
therein). Members of this family have been shown to
homodimerize and heterodimerize as well (3-7). This interaction
between members of this transcription factor family enables them
to regulate a wide variety of genes. Such genes include ones
involved in, but not limited to, the immune and inflanmmatory
responses, cellular adhesion, and cell growth. NF-xB target
sequences have also been found in the enhancer regions of several
viruses implicating a role of NF-xB in viral pathogenesis
(8- 1O).IxB-a and other cytoplasmic inhibitors of this family
including the chicken homologue, pp4O, and the drosophila
homologue, cactus, share highly conserved ankyrin repeats which
are thought to play a role in cytoplasmic compartmentalization
(reviewed in 1 and 11).
IxB-a noncovalently interacts (12) with the NLS (nuclear
localization sequence) of both the p50 and p65 subunits that make
up NF-xB (13). Thus, IxB-a controls the DNA binding activity
of NF-xB by retaining it in the cytoplasm until it is induced to
translocate into the nucleus. When the cell receives signals from
various sources such as cytokines,viruses, UV light, and others
(reviewed in reference 2), NF-xB is released from IxB-a through
an as yet unknown mechanism. IxB-ci is rapidly degraded, and
NF-xB translocates into the nucleus where it binds to its target
sequence and regulates the expression of various target genes
(1 1).
Recently, several groups have suggested that IxB-a and NF-
xB are involved in an autoregulatory pathway (14-17). These
groups demonstrated that induced IxB-a mRNA expression is
contingent upon a loss of IxB-ct protein and subsequent activation
of NF-xB binding activity. To better understand the regulation
of IxB-a by NF-xB, we cloned, sequenced, and analyzed the
human IxB-a promoter. Here we characterize three NF-xB
binding sites in the IxB-a promoter. We show that i) these sites
have different affinities for different complexes of Rel family
members, ii) in transient transfection assays p65 activates the IxB-
a gene and that IxB-a is able to block this activation and iii)
all three NF-xB sites are required for full TNFa -mediated
regulation of this gene.
MATERIALS AND METHODS
Isolation and sequencing of the 5' flaking region of the IxB-c
genomic clone
An Eco RI/PstI fragment containing the 5' end of the IxB-a
cDNA was used to screen an EMBL-3 human placenta genomic
library (a generous gift from C. Rosen) using the techniques
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described by Benton and Davis (18). Two genomic clones were
isolated after screening approximately 1 x 106 phage plaques. A
3kb SacI fragment of one of the genomic clones was identified
by Southern analysis (19) to contain the 5'end of the IxB-a cDNA
and 5' flanking sequences. This 3kb SacI fragment was subcloned
into pUC19 and sequenced in both directions by the Sanger
dideoxy method (20).
Primer extension analysis
A 19-mer oligo, 400R, was designed in the anti-sense orientation
corresponding to nucleotides +83 to + 101 in the published IxB-
cx cDNA (21). This primer was annealed to poly-A+ mRNA
harvested from HeLa cells stimulated with TNFai (lOng/ml,
Genentech) for 30 minutes. Reverse transcriptase was used to
extend the cDNA product using the conditions and protocols
previously described (22).
Preparation of nuclear extracts
Nuclear extracts from HeLa cells stimulated with TNFa were
prepared as previously described (17). Briefly, HeLa cells were
maintained in Eagle's MEM with 10% fetal calf serum, penicillin
(100 U/ml), and streptomycin (100 pg/ml). Cells were stimulated
with TNFa (10 ng/ml) for 15-30 minutes. Cells were then
washed twice with cold PBS, transferred into a 1.5 ml eppendorf
tube, and spun for 5 minutes at 3500 rpm at 4°C. The cell pellet
was resuspended in CE buffer (1OmM Tris, pH 8.0, 60mM KCI,
lmM EDTA, 0.3% NP40, lmM DTT, and 1mM PMSF). Lysed
cells were spun for 5 minutes at 3500 rpm. The supernatant was
removed and the nuclear pellet was washed in Iml of CE buffer
without NP40 then spun for 5 minutes at 2,500 rpm. The nuclei
were resuspended in an equal volume of nuclear extract buffer
(20mM Tris pH 8.0, 1.5mM MgCl2, 0.2mM EDTA, 25%
glycerol, and O.5mM PMSF). SM NaCl was added upon
vortexing to a final concentration of 420mM. Nuclei were left
on the Nutator at 4°C for 20 minutes. After a spin at 12,000
rpm for 15 minutes at 4°C, the nuclear extracts were collected.
Electromobility shift assays (EMSA)
The binding sites for the three NF-xB sites were created by
annealing the oligonucleotides 5'-TCGACCCCAGAGAAATC-
CCCAGCCG-3' and 5'-TCGACGGCTGGGGATTlCTCTGG-
GG-3' for NF-xB site 1, 5'-TCGACGCTTGGAAATTCCC-
CGACCTG-3' and 5'-TCGACAGGTCGGGGAATTTCCAA-
GCG-3' for NF-xB site 2, and 5'-TCGACTCCCTGGGGTTT-
CCCACGATG-3' and 5'-TCGACATCGTGGGAAACCCC-
AGGGAG-3' for NF-xB site 3. 2,000 cpm of the 32P end
labeled binding site oligonucleotide was incubated with 241 of
nuclear extracts, 50mM NaCl, 10 mM Tris pH 7.7, O.5mM
EDTA, lmM DTT, and 21tg poly(dI-dC), and 10% glycerol
before loading on a 0.25 x Tris-borate EDTA native gel.
For the supershift assays, antibodies to pSO, p65, or c-rel
(Rockland, Inc., Boyertownm, PA) were pre-incubated with the
nuclear extract in the reaction conditions mentioned above before
the addition of the labeled probe. Blocking peptides for p5O, p65,
and c-rel were included in the reaction where described.
PCR mutagenesis of the NF-xB sites
Oligonucleotides containing mutations in each of the three NF-
xB sites were used as primers in PCR reactions to generate site
specific mutants as previously described (23). The
oligonucleotides used to create a mutant NF-xB site 1 are 5'-C-
gaTCTGGGG-3', a mutant NF-xB site 2 are 5'-GCTTGcAA-
ATTggCCGAGCC-3' and 5'-GGCTCGGccAATTTgCAAG-
C-3', and a mutant NF-xB site 3 are 5'-GacAcAggaaAGGGG-
AAAGAAGGCTCA-3' and 5'-ttccTgTgtCACGATCGATT-
TGAATT-3' (mutations in the NF-xB sites are in lower case
type). The 5' primer, 5'-CCCAAGCTTGCAGCCGACGACC-
CC-3', contains a HindHI site and the 3' primer, 5'-GGGGTC-
TAGAGGGCGCTGCTGCGGGT-3', contains a XbaI site. These
sites were used to clone the wildtype and mutant PCR products
into pBL-CAT (24). These constructs were then sequenced using
the Sanger dideoxy method (20) to confirm their site specific
mutations. These constructs encompass regions -342 to + 115
of the IxB-a gene.
Transient transfection reactions and quantitation of CAT
activity
Hela cells were cultured in Eagles MEM media supplemented
with 10% fetal calf serum, penicillin (100 U/ml), and
streptomycin (100 ug/ml). The calcium phosphate method was
used to transfect the HeLa cells with 10kg of the IxB-u promoter-
CAT construct plus pCMV4T-p65 (0.5,ug), pCMV4T alone
(2.5ig), or pCMV4T-p65 (0.5,ug) and pIxB-a (24g). The total
amount of DNA transfected was held constant to 12.5 jug with
the pCMV4T empty vector. IxB-a promoter-CAT construct
contains the -342 to + 115 region of the IxB-oz gene cloned into
the HindJI/XbaI site of pBL-CAT. The pCMV4T, pCMV4T-
p65, and pIxB-a expression vectors have been previously
described (25,13). CAT activity was determined by a previously
described method (26) and standardized for protein levels (27).
The K562 cells were cultured in DMEM supplemented with
10% fetal calf serum, penicillin (100 U/ml), and streptomycin
(100 pg/ml). 0l,g of wildtype or each of the mutant constructs
generated by PCR mutagenesis described above were
electroporated into 2 x 106 K562 cells using the BioRad gene
pulser at a setting of 300V, 960,uF. 24 hours after transfection,
TNFa (10 ng/ml, Genetech) was added to the cells. 24 hours
following TNFca stimulation, the cells were harvested, rinsed in
PBS, and cell extracts were obtained by freezing and thawing
the cells three times for 5 minutes in a dry ice-ethanol bath.
The cell extracts were incubated with 14C chloramphenicol
(Amersham) and Acetyl CoA (Boehringher Mannheim) at 37°C
overnight. Acetylated and non-acetylated forms *of
chloramphenicol were separated by thin layer chromotography.
CAT activity was determined by autoradiography and analyzed
by densitometry.
RESULTS
Cloning of the human IxB-a promoter
A human placenta genomic DNA library was screened using a
5' EcoRI/PstI fragment from the MAD-3/IxB-a cDNA (21).
Two genomic clones were isolated and one of them (clone X-7),
containing a 3kb SacI fragment encoding the 5'end of the cDNA,
was further characterized. Sequence analysis showed that the
potential 5' flanking sequence contained several putative
transcription factor binding sites including ones for SpI and NF-
xB (Fig.1).
To identify the transcription start site, primer extension analysis
was performed. A sequence at position +83 to +101 in the
cDNA were used to design an anti-sense oligo, 400R, which was
used as a primer to extend poly-A+ mRNA from TNFa
stimulated HeLa cells . The primer extension product ends justCCCAGAtctATgCtCAGCCAG-3' and 5'-CTGGCTGaGcATa-


































Figure 1. Nucleotide sequence of the 5' flanking region of the IxB-a gene. The
putative TATA box is in bold type next to the putative transcription start site
indicated by the arrow. The three NF-xB sites 1, 2, and 3 are circled and another
one, 2A, is labeled. A Spl site between NF-xB sites 1 and 2 is double underlined.
The translation start site is also highlighted at + 132.
adjacent to a TATA-like box (Fig. 2). To confirm this
transcription start site and to rule out the possibility that an intron
may exist between the 400R oligo and the true transcription start
site, RNAse protection assays were done. The size of the
protected fragmet coincided with the start site identified in the
primer extension assay (data not shown). Thus, transcription
appears to begin 36 bases beyond the published cDNA sequence
(21) and close to a TATA-like element.
The NF-xB binding sites in the IxB-ca promoter bind different
members of the Rel family
Computer analysis of the IxB-a promoter originally identified
four potential NF-xB binding sites, 1, 2, 2A, and 3 (see Fig.
1). EMSAs (Electrophoretic Mobility Shift Assays) were
performed using oligonucleotides to these sites and nuclear
extracts from TNFa stimulated HeLa cells. These NF-xB binding
sites are not identical in sequence, as shown in Figure 1, and
do not bind to identical protein complexes (Fig. 3). The NF-xB
site 1 forms a faster migrating minor complex, I, and a slower
migrating major complex, II. NF-xB sites 2 and 3 have similar
affinities for the proteins which bind to the NF-xB site 1 and
these probes bind to an additional protein factor, IH, which
migrates even slower than the ones mentioned in the above text.
The fourth putative NF-xB site, 2A, did not consistently bind
to any protein complexes (data not shown).
5' +1 400R 3'
...tttatagGgcgccgcgg...
Figure 2. Identification of the transcription start site using primer extension
analysis. The primer extension product was run on a 5% sequencing gel alongside
a dideoxy sequencing reaction of the IxB-ca genomic clone using the same primer
that was used in the primer extension reaction. Shown below is a schematic diagram
of the primer used in both reactions and the mapping of the transcription start site.
In an attempt to identify the proteins bound to NF-xB sites
1, 2, and 3, antibodies to c-rel and the p5O and p65 subunits
of NF-xB were pre-incubated with the nuclear extracts from
HeLa cells stimulated with TNFct prior to electrophoresis. Both
protein complexes which bind to NF-xB site 1 include p5O (Fig.
4). The antibody to p5O is able to shift the faint faster migrating
complex I as well as the darker slower migrating complex II (Fig.
4, lane 3). Incubating the p5O antibody with its blocking peptide
is able to impair its ability to supershift both bands (lane 4).
Antibodies to p65 or c-rel do not affect complex I but shift
complex II (lanes 1, 2, 5, 6). Since the c-rel antibody weakly
shifts complex II, the data suggest that complex II is
predominantly composed of p50 complexed to p65 and that this
complex also contains trace p5O/c-rel or p65/c-rel heterodimers.
These data also suggest that complex I is primarily comprised
of p50 proteins, presumably pSO/pSO homodimers, although the
possibility of p5O/p52 heterodimers has not been ruled out.
Protein complex I described above also binds to NF-xB sites
2 and 3 and is supershifted by the p50 antibody (Fig. 4, lanes
9 and 15) but not the p65 and c-rel antibodies (lanes 7, 11, 13,
and 17). Complex II is also able to bind NF-xB sites 2 and 3,
and consistent with the data mentioned above, this complex is
recognized by antibodies to p50, p65, and c-rel (lanes 7-18)
. These observations provide more evidence that complex I
consists predominantly of p50 protein and that complex II is a
mixture of p50 complexed with either p65 or c-rel.
Complex III, however, is observed with NF-xB sites 2 and
3, but not with NF-xB site 1. This complex is recognized by
the antibodies to p65 and c-rel (lanes 7, 11 13, and 17). When
G A T C
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the blocking peptides for the p65 and c-rel antibodies are included
in the reaction, they hinder the ability of their respective
antibodies to supershift this complex (lanes 8, 12, 14, and 18).
NFKB-2
This complex may also contain p5O since the antibody to p5O
also shifts this complex, albeit weakly (lanes 9, 10, 15, and 16).
Therefore, although p5O may bind to this site, complex 1m mainly
contains p65 and c-rel proteins which may be present as
homodimers or heterodimers.






Figure 3. EMSAs (Electophoretic Mobility Shift Assay) of the putative NF-xB
binding sites. Nuclear extracts from TNFca (10 ng/nl, Genentech) stimulated and
nonstimulated HeLa cells were incubated with 32p labeled oligos made to each
of the three putative NF-xB binding sites. The protein/DNA complexes were
analyzed on a 0.25 x Tris-borate EDTA native gels. The arrows indicate protein
complexes I and II bind to all of these sites, while complex In only binds to
NF-xB sites 2 and 3. The MHC class I NF-xB site was used as a control.
NFKBi
NF-xB activates IxB-a gene expression
To further characterize the NF-xB sites in the IxB-a promoter,
the 5' flanking region (to position -342bp) was cloned into a
CAT reporter construct. Since the p65 subunit of NF-xB has
been shown to be a potent transcriptional activator, the IxB-ai
promoter-CAT construct was transiently transfected into HeLa
cells along with a p65 expression plasmid. The p65 subunit of
NF-xB was able to stimulate the expression of the CAT gene
by 10 fold over transfection of the IxB-a promoter-CAT construct
plus the empty pCMV-4T vector (Fig. 5). To further demonstrate
that NF-xB is involved in the regulation of the IxB-a gene, the
promoter construct was cotransfected together with an IxB-a
expression plasmid in addition to a p65 expression plasmid. As
expected, IxB-a expression was able to inhibit the expression
of its own promoter and CAT activity was inhibited to baseline
levels of the IxB-a promoter CAT construct plus pCMV-4T.
These data support the idea that NF-xB and IxB-a are involved
in an autoregulatory loop.
To determine whether all three NF-xB sites are required for
the regulation of the IxB-a gene, we used PCR site directed
mutagenesis to alter the NF-xB sites at the residues which have
been shown to interact with NF-xB. The wildtype and mutant
NFKB-2 NFKcB-3
Antibody p65 p65 p50 p50 c:-rci :-r e
Peptide - + - + +
pf;5 p65 p5O p5O c-red c-rel
- + - + - +
p65 p65 p50 p50 c- rel c-rel
- + - 4 - +;i.
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Figure 4. Identification of the protein complexes bound to NF-xB sites 1, 2 and 3. Antibodies to the p50 and p65 subunits of NF-xB and c-rel were used to identify
the protein/DNA complexes bound to the putative NF-xB sites. Blocking peptides to these antibodies were used in blocking reactions to confirm the specificity of
the antibodies. Nuclear extracts from TNFa stimulated HeLa cells were first incubated with the specified antibodies or pre-immune serum in the presence or absence
of their blocking peptides. These reactions were then incubated with 32p labeled probe to NF-xB sites 1(lanes 1-6), 2 (lanes 7-12), or 3 (lanes 13-18) and analyzed
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IxB-a promoter-CAT constructs were transfected into K562 cells
and treated with TNFca, a known inducer of NF-xB activity. The
wildtype promoter-CAT construct was inducible following TNFa
stimulation (Fig. 6, lane 4). When NF-xB sites 1 and 2 were
mutated, however, the IxB-ca promoter-CAT construct was no
longer responsive to TNFa stimulation which resulted in the
decrease of CAT activity (Fig. 6, lanes 6 and 8). Mutating NF-
xB site 3 also affected the ability of the IxB-ca promoter-CAT
construct to respond to TNFa (Fig. 6, lane 10), although mutating
this site was not as detrimental as mutating NF-xB sites 1 or
2. These data demonstrate that NF-xB plays a role in regulating
the IxB-a gene and that NF-xB sites 1 and 2 are required for
TNFa-mediated gene activation, but NF-xB site 3 may play a
lesser role in this response.
DISCUSSION
Previous studies have shown a correlation between loss of IxB-
a protein in the cytoplasm and the reappearance of IxB-a
message (14-17). This process presumably requires induced NF-
xB binding activity. Other studies have shown that the p50
promoter is regulated by NF-xB (28,29). These data suggest that
NF-xB and IxB-az are involved in an autoregulatory pathway
to ensure the proper balance of NFxB and IxB-a in the cell.
Our experiments here show direct interaction between NF-xB
complexes and their target sites in the IxB-a promoter resulting
in the activation of the IxB-a gene. We further show that there
are three NF-xB sites in the IxB-a promoter which bind various
p50, p65, and c-rel complexes in nuclear extracts from HeLa
cells stimulated with TNFox and that mutating any one of these
sites affects TNFca-mediated activation of the IxB-caa gene.
The NF-xB site 2 in this report has also been recently
characterized in the porcine IxB-a promoter by de Martin et al.
(30), in the murine promoter by Chiao et al. (31), and in the
human promoter by Le Bail et al. (32). The latter group also
identify another NF-xB site which corresponds to NF-xB site
3 in this report. In addition to these sites, we present additional
sequence and characterize another NF-xB target sequence in the
IxB-a promoter, NF-xB site 1, and show that it only binds p50
complexed with itself, p65, or c-rel from nuclear extracts of
TNFa stimulated HeLa cells. The other two NF-xB sites 2 and
3, are able to bind to the same p50 protein complexes bound
to NF-xB site 1 and also bind additional protein complexes
predominantly comprised of p65 and c-rel homodimers or
heterodimers. These data taken collectively indicate that the IxB-a
gene is regulated by at least three fuctional NF-xB sites which
have different affinities for various members of the Rel family.
Since all three sites are essential for strong activation of the IxB-a
gene following TNFa stimulation, there may be a cooperative
functional interaction between the protein complexes bound to
these sites.
We have shown that the IxB-a gene is regulated by NF-xB
through at least three NF-xB sites, however, this gene may also
be regulated by other transcription factors. There is an intriguing
possibility that interactions between NF-xB and Spl might be
involved in regulating this gene. An SpI site exists between NF-
xB sites 1 and 2 (data not shown). SpI has been shown to interact
with p65/p52 heterodimers on the HIV-1 LTR to activate
transcription (33). The 3bp spacing between SpI and NF-xB sites
in the HIV-1 LTR seems to be very important. The spacing
between this Spi site and the NF-xB site 1 in the IxB-a promoter
is similar to that in the HIV-1 LTR, suggesting a possible
interaction between Spl and NF-xB protein complexes which
bind to this site (33). The other NF-xB target sequence, site 2,
is 10bp away from this Spl site. Since this distance has been
shown to affect the transcriptional inducibility by these two
transcription factors on the HIV-1 LTR (33), it seems unlikely
that NF-xB bound to this site interacts with Spl to activate
transcription of the IxB-a gene.
The NF-xB sites, the Spi site, and the putative TATA box
as well as the IxB-a promoter as a whole are highly conserved
between the porcine and the human IxB-a promoter (79.9%
sequence homology). Homology decreases noticeably following
an Alu repeat insertion in the porcine promoter at approximately
-400 relative to the transcription start site identified here. There
seems to be a discrepency as to where transcription of the IxB-
a gene starts. We have mapped the transcription start site adjacent
pBL-CAT Wildtype NFKB NFKB NFKBsite 2 site 1 site 3
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Figure 5. Regulation of the IxB-a gene by NF-xB. (A) HeLa cells were transfected
using the calcium phosphate method with an IxB-a promoter-CAT construct plus
a p65 expression vector alone, p65 and IxB-ci expression vectors, or an empty
expression vector, CMV-4T. 24 hours after transfection, cell extracts were
harvested and CAT activity was determined. The fold induction is relative to
the CAT activity of the CMV-4T empty vector. The relative CAT activities
presented are representive of three independent experiments.
Fold Induction 1 .0 1 .0 1 .2 6.9 0.76 0.83 0.89 1.2 1 .0 2.0
Figure 6. All three NF-xB sites in the IxB-c promoter are required for full
activation of the IxB-ci promoter-CAT construct following TNFa stimulation.
K562 cells were transfected by electroporation with an IxB-oe wildtype promoter-
CAT construct or an IxB-a promoter-CAT construct containing mutations in either
NF-xB sites 1, 2, or 3. 24 hours after transfection, TNFcs (10 ng/ml) was added
to the media and after another 24 hours, cell extracts were harvested. CAT activity
was determined by thin layer chromotography and autoradiography. The fold
induction was determined by densitometry and is relative to the CAT activity
of the pBL-CAT vector in unstimulated cells which is arbitrarily set at 1.0. These
values are an average of three independent experiments which did not vary from
each other by more than 20%.
TNFax
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to a TATA-like box by primer extension using poly-A+ RNA
from TNFco stimulated HeLa cells. LeBail et al. (32) use total
RNA from PMA induced THP1 cells to identify two transcription
start sites, one upstream and one downstream of the putative
TATA-box. de Martin et al. (30) and Chiao et al. (31) likewise
identify a single start site downstream of the putative TATA-
box in the procine and murine IxB-a promoters, respectively.
The start site mapped upstream of the TATA-like box and the
various transcription start sites in the IxB-a promoter seem to
be characteristic of a TATA-less promoter and allow for some
speculation about the function of the TATA-like box. It seems
plausible that the TATA-like box is not functional and that the
IxB-ca gene may be regulated by a TATA-less promoter or that
there are different start sites depending on the inducer of IxB-a
message and source of the RNA.
There also lies the possibility that other cis-acting elements may
be required for the transcription of this gene. There is a putative
NF-xB site in the first intron of the IxB-a gene (manuscript in
prep). This putative NF-xB site in the first intron is identical
to one of the NF-xB sites found in the HIV-l LTR (9). It is
possible that the NF-xB sites in the first intron may act as
enhancers and may augment the induction of this gene by TNFct
or other cytokines. Although further studies need to be done in
order to fully understand the roles of other transcription factors
and cis elements in the regulation of the IxB-cx gene our studies
show that NF-xB and Rel proteins regulate IxB-a gene
expression.
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